These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15390130)

  • 1. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease.
    Pezzella FR; Colosimo C; Vanacore N; Di Rezze S; Chianese M; Fabbrini G; Meco G
    Mov Disord; 2005 Jan; 20(1):77-81. PubMed ID: 15390130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Problematic gambling on dopamine agonists: Not such a rarity.
    Grosset KA; Macphee G; Pal G; Stewart D; Watt A; Davie J; Grosset DG
    Mov Disord; 2006 Dec; 21(12):2206-8. PubMed ID: 17013907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study.
    Bearn J; Evans A; Kelleher M; Turner K; Lees A
    Drug Alcohol Depend; 2004 Dec; 76(3):305-10. PubMed ID: 15561481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of pathological gambling in patients with Parkinson's disease.
    Avanzi M; Baratti M; Cabrini S; Uber E; Brighetti G; Bonfà F
    Mov Disord; 2006 Dec; 21(12):2068-72. PubMed ID: 17044068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulse control disorders in Parkinson's disease: prevalence and possible risk factors.
    Weintraub D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S110-3. PubMed ID: 20082968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset.
    Giladi N; Weitzman N; Schreiber S; Shabtai H; Peretz C
    J Psychopharmacol; 2007 Jul; 21(5):501-6. PubMed ID: 17446202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire.
    Pezzella FR; Di Rezze S; Chianese M; Fabbrini G; Vanacore N; Colosimo C; Meco G
    Neurol Sci; 2003 Oct; 24(3):205-6. PubMed ID: 14598089
    [No Abstract]   [Full Text] [Related]  

  • 10. Hedonistic homeostatic dysregulation in Parkinson's disease and excess dopamine replacement therapy.
    Grosset K; Grosset D
    Mov Disord; 2005 Sep; 20(9):1230-1. PubMed ID: 16037920
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.
    Pacchetti C; Manni R; Zangaglia R; Mancini F; Marchioni E; Tassorelli C; Terzaghi M; Ossola M; Martignoni E; Moglia A; Nappi G
    Mov Disord; 2005 Nov; 20(11):1439-48. PubMed ID: 16028215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease.
    Evans AH; Lawrence AD; Potts J; Appel S; Lees AJ
    Neurology; 2005 Nov; 65(10):1570-4. PubMed ID: 16301483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.
    Evans AH; Katzenschlager R; Paviour D; O'Sullivan JD; Appel S; Lawrence AD; Lees AJ
    Mov Disord; 2004 Apr; 19(4):397-405. PubMed ID: 15077237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Parkinson's disease a homogeneous disorder--what is the burden of Parkinson's disease in India.
    Ghosh B; Mishra A; Sengupta P
    J Indian Med Assoc; 2005 Mar; 103(3):146, 148, 150 passim. PubMed ID: 16173291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field.
    Ambermoon P; Carter A; Hall WD; Dissanayaka NN; O'Sullivan JD
    Addiction; 2011 Feb; 106(2):283-93. PubMed ID: 21134016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients.
    Tanasanvimon S; Ayuthaya NI; Phanthumchinda K
    J Med Assoc Thai; 2007 Nov; 90(11):2277-83. PubMed ID: 18181307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management.
    Ceravolo R; Frosini D; Rossi C; Bonuccelli U
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S111-5. PubMed ID: 20123548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonists and therapy compliance.
    Grosset D
    Neurol Sci; 2008 Dec; 29 Suppl 5():S375-6. PubMed ID: 19381766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease.
    Bandini F; Primavera A; Pizzorno M; Cocito L
    Parkinsonism Relat Disord; 2007 Aug; 13(6):369-71. PubMed ID: 17049455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.